P-BCMA-ALLO1
Phase 1- Indications
- Multiple myeloma
Company intelligence / Profile preview
Poseida Therapeutics
San Diego, California, United Statesposeida.com ↗
- Ownership
- Public · PSTX
- Employees
- ~150
- Development stage
- Phase 1
01
Overview
Poseida has demonstrated promising early clinical results with its allogeneic CAR-T cell therapy P‑BCMA‑ALLO1 in multiple myeloma patients. The program received Regenerative Medicine Advanced Therapy designation from the FDA in September 2024. The company’s pipeline includes both hematologic malignancy and solid tumor candidates as well as gene therapies for rare diseases.
- Therapeutic areas
- OncologyImmunologyRare Diseases
- Modalities
- Allogeneic CAR-T cell therapiesGene therapies (in vivo and ex vivo)Genome editing technologies (Cas-CLOVER, piggyBac DNA Delivery System)Nanoparticle-based delivery systems
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
Takeda PharmaceuticalsXyphos BiosciencesAstellas Pharmaprevious partnership with Roche before acquisition
04
Financials
- Market cap
- $925.9M
- Total revenue
- $71.7M
- Enterprise value
- $777.8M
Beyond the preview
Go deeper on Poseida Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Poseida Therapeutics.